))
From Podocyte to Patient: The Pathophysiology of FSGS
Manage episode 485312078 series 3563882
Content provided by Travere Therapeutics. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Travere Therapeutics or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
In this episode, Drs. Tobias Huber and Chris Gisler take a deep dive into the critical role of podocytes in kidney health and their involvement in the development and progression of FSGS. They explore how podocyte injury leads to the breakdown of the glomerular filtration barrier and the emergence of proteinuria. They highlight the intertwined roles of endothelin 1 and angiotensin II in worsening podocyte dysfunction and driving disease progression. They discuss current and emerging data, treatment options, and biomarkers, including findings from Dr. Huber’s latest research. Lastly, they emphasize the value of proteinuria as both a marker and mediator of podocyte damage, reinforcing its role as a key therapeutic target in FSGS.
Key Takeaways:
- Podocytes are essential for maintaining the integrity and health of the kidney.
- Podocyte damage directly contributes to proteinuria and disease progression.
- Proteinuria is both a symptom and a driver of FSGS disease progression.
- Endothelin 1 and angiotensin II promote podocyte dysfunction.
Speakers:
- Tobias Huber is the Chair of the Center of Internal Medicine at University Medical Center Hamburg-Eppendorf, Germany and president of the International Society of Glomerular Disease.
- Chris Gisler is a medical director at Travere Therapeutics and a community nephrologist practicing in Pittsburgh.
6 episodes
Share
